$RGBP
Regen BioPharma Inc Stock $rgbp

$rgbp Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000160706224000131 Filed on April 24, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q3
Revenue	$59.07K	$31.64K	$59.37K
YoY Change	-0.01%	0.0%	0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$134.5K	$120.0K	$83.12K
YoY Change	35.59%	18.27%	-10.51%
% of Gross Profit
Research & Development	$32.50K	$40.13K	$35.34K
YoY Change	-27.78%	10.12%	-45.01%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$32.50K	$40.13K	$118.5K
YoY Change	-77.46%	10.12%	-24.62%
Operating Profit	-$108.0K	-$101.1K
YoY Change	26.79%	28.19%
Interest Expense	-$22.15K	$17.06K	-$15.94K
YoY Change	57.54%	41.19%	-124.43%
% of Operating Profit
Other Income/Expense, Net		$0.00	-$250.0K
YoY Change			449.45%
Pretax Income	-$130.1K	-$122.5K	-$325.0K
YoY Change	31.14%	122.75%	316.54%
Income Tax
% Of Pretax Income
Net Earnings	-$130.1K	-$122.5K	-$325.0K
YoY Change	31.14%	122.77%	316.56%
Net Earnings / Revenue	-220.3%	-387.08%	-547.46%
Basic Earnings Per Share	-$0.03
Diluted Earnings Per Share	-$0.03	-$0.03	-$0.07
COMMON SHARES
Basic Shares Outstanding	4.214M shares	3.941M shares
Diluted Shares Outstanding	4.214M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$61.85K	$78.12K	$121.0K
YoY Change	8863.77%	-10.92%	136.41%
Cash & Equivalents	$61.85K	$78.11K	$121.0K
Short-Term Investments
Other Short-Term Assets	$23.42K	$5.200K	$10.00K
YoY Change	335.32%	-69.82%	-67.69%
Inventory
Prepaid Expenses		$200.00	$0.00
Receivables	$67.15K	$39.72K	$0.00
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$152.4K	$123.0K	$131.0K
YoY Change	143.4%	-33.15%	-61.05%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$17.73K	$17.73K	$222.6K
YoY Change	-92.03%	-92.03%	0.0%
Other Assets
YoY Change
Total Long-Term Assets	$17.73K	$17.73K	$222.6K
YoY Change	-92.03%	-92.03%	0.0%
TOTAL ASSETS
Total Short-Term Assets	$152.4K	$123.0K	$131.0K
Total Long-Term Assets	$17.73K	$17.73K	$222.6K
Total Assets	$170.2K	$140.8K	$353.6K
YoY Change	-40.34%	-65.38%	-36.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$29.42K	$29.80K	$29.67K
YoY Change	0.05%	-12.48%	3.04%
Accrued Expenses	$1.662M	$1.645M	$1.645M
YoY Change	1.99%	1.79%	-17.84%
Deferred Revenue
YoY Change
Short-Term Debt	$219.2K	$50.21K	$96.71K
YoY Change	115.54%	-50.63%	5555.56%
Long-Term Debt Due	$499.9K	$499.9K	$509.9K
YoY Change	-1.96%	-1.96%	-59.93%
Total Short-Term Liabilities	$5.328M	$5.173M	$5.308M
YoY Change	0.26%	-3.06%	-38.24%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$143.7K	$0.00
YoY Change
Other Long-Term Liabilities		$0.00	$149.6K
YoY Change
Total Long-Term Liabilities	$0.00	$143.7K	$149.6K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.328M	$5.173M	$5.308M
Total Long-Term Liabilities	$0.00	$143.7K	$149.6K
Total Liabilities	$5.328M	$5.317M	$5.458M
YoY Change	0.26%	-0.37%	-36.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$20.35M	-$20.22M	-$19.75M
YoY Change	4.77%	4.64%	-5.53%
Common Stock	$25.33K	$26.78K	$352.00
YoY Change	7370.8%	7800.0%	-99.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.158M	-$5.176M	-$5.104M
YoY Change
Total Liabilities & Shareholders Equity	$170.2K	$140.8K	$353.6K
YoY Change	-40.34%	-65.38%	-36.74%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q3
OPERATING ACTIVITIES
Net Income	-$130.1K	-$122.5K	-$325.0K
YoY Change	31.14%	122.77%	316.56%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$172.6K	-$209.3K	-$23.92K
YoY Change	98.36%	294.65%	-71.95%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	156.3K	162.9K	143.8K
YoY Change		62.93%	28650.0%
NET CHANGE
Cash From Operating Activities	-172.6K	-209.3K	-23.92K
Cash From Investing Activities
Cash From Financing Activities	156.3K	162.9K	143.8K
Net Change In Cash	-16.26K	-46.39K	119.8K
YoY Change	-81.31%	-198.79%	-300.42%
FREE CASH FLOW
Cash From Operating Activities	-$172.6K	-$209.3K	-$23.92K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001589150
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2023Q1	RGBP	Common Shares Issued Pursuant To Round Up Provision CommonSharesIssuedPursuantToRoundUpProvision		usd
CY2023Q1	RGBP	Preferred Shares Issued Pursuant To Round Up Provision PreferredSharesIssuedPursuantToRoundUpProvision		usd
CY2023Q1	RGBP	Reverse Stock Split Value1 ReverseStockSplitValue1		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	333-191725
	dei	Entity Registrant Name EntityRegistrantName	REGEN BIOPHARMA, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-5192997
	dei	Entity Address Address Line1 EntityAddressAddressLine1	4700 Spring Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	St 304
	dei	Entity Address City Or Town EntityAddressCityOrTown	La Mesa
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91942
	dei	City Area Code CityAreaCode	619
	dei	Local Phone Number LocalPhoneNumber	722-5505
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4114622	shares
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	us-gaap	Cash Cash	78115	usd
CY2023Q3	us-gaap	Cash Cash	121037	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	39723	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2023Q3	RGBP	Notes Receivable Related Party Current NotesReceivableRelatedPartyCurrent	0	usd
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	200	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	0	usd
CY2024Q1	us-gaap	Prepaid Rent PrepaidRent	5000	usd
CY2023Q3	us-gaap	Prepaid Rent PrepaidRent	10000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	123037	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	131037	usd
CY2024Q1	RGBP	Investment Securities Related Party InvestmentSecuritiesRelatedParty	17733	usd
CY2023Q3	RGBP	Investment Securities Related Party InvestmentSecuritiesRelatedParty	222580	usd
CY2024Q1	us-gaap	Other Assets OtherAssets	17733	usd
CY2023Q3	us-gaap	Other Assets OtherAssets	222580	usd
CY2024Q1	us-gaap	Assets Assets	140770	usd
CY2023Q3	us-gaap	Assets Assets	353617	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	29798	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	29674	usd
CY2024Q1	us-gaap	Notes And Loans Payable NotesAndLoansPayable	49210	usd
CY2023Q3	us-gaap	Notes And Loans Payable NotesAndLoansPayable	95710	usd
CY2024Q1	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	4241	usd
CY2023Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	4241	usd
CY2024Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	342416	usd
CY2023Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	342588	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1256630	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1256630	usd
CY2024Q1	RGBP	Other Accrued Expenses OtherAccruedExpenses	41423	usd
CY2023Q3	RGBP	Other Accrued Expenses OtherAccruedExpenses	41423	usd
CY2024Q1	us-gaap	Bank Overdrafts BankOverdrafts	1000	usd
CY2023Q3	us-gaap	Bank Overdrafts BankOverdrafts	1000	usd
CY2024Q1	RGBP	Due To Investor DueToInvestor	20000	usd
CY2023Q3	RGBP	Due To Investor DueToInvestor	20000	usd
CY2024Q1	RGBP	Unearned Income UnearnedIncome	1528451	usd
CY2023Q3	RGBP	Unearned Income UnearnedIncome	1591731	usd
CY2024Q1	RGBP	Unearned Income Related Party UnearnedIncomeRelatedParty	0	usd
CY2023Q3	RGBP	Unearned Income Related Party UnearnedIncomeRelatedParty	15126	usd
CY2024Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	1400000	usd
CY2023Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	1400000	usd
CY2024Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	499880	usd
CY2023Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	499880	usd
CY2024Q1	RGBP	Convertible Notes Payable Related Parties Less Unamortized Discount ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscount	0	usd
CY2023Q3	RGBP	Convertible Notes Payable Related Parties Less Unamortized Discount ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscount	10000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5173049	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5308003	usd
CY2024Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	143685	usd
CY2023Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	149614	usd
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	143685	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	149614	usd
CY2024Q1	us-gaap	Liabilities Liabilities	5316734	usd
CY2023Q3	us-gaap	Liabilities Liabilities	5457617	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5800000000	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5800000000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4114622	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3506366	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	412	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	352	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	800000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	800000000	shares
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	40	usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	40	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	14308349	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	13908141	usd
CY2024Q1	us-gaap	Other Additional Capital OtherAdditionalCapital	736326	usd
CY2023Q3	us-gaap	Other Additional Capital OtherAdditionalCapital	736326	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-20221096	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19748863	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-5175963	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-5104000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	140770	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	353617	usd
CY2024Q1	us-gaap	Revenues Revenues	31640	usd
CY2023Q1	us-gaap	Revenues Revenues	31640	usd
	us-gaap	Revenues Revenues	63280	usd
	us-gaap	Revenues Revenues	63280	usd
CY2024Q1	RGBP	Revenues Related Party RevenuesRelatedParty	27425	usd
CY2023Q1	RGBP	Revenues Related Party RevenuesRelatedParty	27425	usd
	RGBP	Revenues Related Party RevenuesRelatedParty	54849	usd
	RGBP	Revenues Related Party RevenuesRelatedParty	54849	usd
CY2024Q1	RGBP	Total Revenues TotalRevenues	59065	usd
CY2023Q1	RGBP	Total Revenues TotalRevenues	59065	usd
	RGBP	Total Revenues TotalRevenues	118129	usd
	RGBP	Total Revenues TotalRevenues	118129	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40133	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36446	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	87661	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	131959	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9387	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18660	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21806	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	27398	usd
CY2024Q1	us-gaap	Professional Fees ProfessionalFees	93400	usd
CY2023Q1	us-gaap	Professional Fees ProfessionalFees	67800	usd
	us-gaap	Professional Fees ProfessionalFees	200300	usd
	us-gaap	Professional Fees ProfessionalFees	471480	usd
CY2024Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	17215	usd
CY2023Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	15000	usd
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	32215	usd
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	30000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	160135	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	137906	usd
	us-gaap	Costs And Expenses CostsAndExpenses	341981	usd
	us-gaap	Costs And Expenses CostsAndExpenses	660837	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-101071	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-78842	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-223852	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-542708	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	17063	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	12085	usd
	us-gaap	Interest Expense InterestExpense	34828	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-122473	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-5175963	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-8036059	usd
CY2022Q4	RGBP	Preferred Shares Issued For Nonemployee Services PreferredSharesIssuedForNonemployeeServices	300000	usd
CY2022Q4	RGBP	Preferred Shares Issued For Debt PreferredSharesIssuedForDebt	761500	usd
CY2022Q4	RGBP	Preferred Shares Issued For Interest PreferredSharesIssuedForInterest	380262	usd
CY2022Q4	RGBP	Common Shares Issued For Interest CommonSharesIssuedForInterest	25369	usd
CY2022Q4	RGBP	Preferred Shares Issued For Nonemployee Services1 PreferredSharesIssuedForNonemployeeServices1	48372	usd
CY2022Q4	us-gaap	Profit Loss ProfitLoss	1635730	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-4884827	usd
CY2023Q1	RGBP	Reverse Stock Split Value ReverseStockSplitValue	0	usd
	us-gaap	Interest Expense InterestExpense	29444	usd
CY2024Q1	RGBP	Interest Expense Attributable To Amortization Of Discount InterestExpenseAttributableToAmortizationOfDiscount	-4339	usd
	RGBP	Interest Expense Attributable To Amortization Of Discount InterestExpenseAttributableToAmortizationOfDiscount	-8706	usd
	us-gaap	Debt Securities Unrealized Gain Loss DebtSecuritiesUnrealizedGainLoss	-204847	usd
CY2023Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	35949	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	2151755	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1150	usd
CY2024Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-21402	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	23864	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-248380	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	2123460	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-122473	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-54978	usd
	us-gaap	Net Income Loss NetIncomeLoss	-472233	usd
	us-gaap	Net Income Loss NetIncomeLoss	1580752	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-122473	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-54978	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-472233	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1391061	usd
CY2024Q1	RGBP	Basic And Fully Diluted Earnings Loss Per Share BasicAndFullyDilutedEarningsLossPerShare	-0.03
CY2023Q1	RGBP	Basic And Fully Diluted Earnings Loss Per Share BasicAndFullyDilutedEarningsLossPerShare	-0.03
	RGBP	Basic And Fully Diluted Earnings Loss Per Share BasicAndFullyDilutedEarningsLossPerShare	-0.12
	RGBP	Basic And Fully Diluted Earnings Loss Per Share BasicAndFullyDilutedEarningsLossPerShare	0.41
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3941013	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1656429	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3831431	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3364578	shares
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-5104000	usd
CY2023Q4	RGBP	Shares Issued For Cash Shares SharesIssuedForCashShares	16710	shares
CY2023Q4	RGBP	Shares Issued For Cash SharesIssuedForCash	22726	usd
CY2023Q4	RGBP	Shares Issued For Cash Shares2 SharesIssuedForCashShares2	35785	shares
CY2023Q4	RGBP	Shares Issued For Cash2 SharesIssuedForCash2	46091	usd
CY2023Q4	RGBP	Shares Issued For Cash Shares3 SharesIssuedForCashShares3	31732	shares
CY2023Q4	RGBP	Shares Issued For Cash3 SharesIssuedForCash3	38205	usd
CY2023Q4	RGBP	Shares Issued For Cash Shares4 SharesIssuedForCashShares4	33989	shares
CY2023Q4	RGBP	Shares Issued For Cash4 SharesIssuedForCash4	32629	usd
CY2023Q4	RGBP	Shares Issued For Cash Shares5 SharesIssuedForCashShares5	43297	shares
CY2023Q4	RGBP	Shares Issued For Cash5 SharesIssuedForCash5	38101	usd
CY2023Q4	RGBP	Shares Issued For Cash Shares6 SharesIssuedForCashShares6	82686	shares
CY2023Q4	RGBP	Shares Issued For Cash6 SharesIssuedForCash6	34543	usd
CY2023Q4	us-gaap	Profit Loss ProfitLoss	-349760	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-5241463	usd
CY2024Q1	RGBP	Shares Issued For Cash Shares7 SharesIssuedForCashShares7	94883	shares
CY2024Q1	RGBP	Shares Issued For Cash7 SharesIssuedForCash7	39638	usd
CY2024Q1	RGBP	Shares Issued For Cash Shares8 SharesIssuedForCashShares8	82643	shares
CY2024Q1	RGBP	Shares Issued For Cash8 SharesIssuedForCash8	44297	usd
CY2024Q1	RGBP	Shares Issued For Cash Shares9 SharesIssuedForCashShares9	40229	shares
CY2024Q1	RGBP	Shares Issued For Cash9 SharesIssuedForCash9	19614	usd
CY2024Q1	RGBP	Shares Issued For Cash Shares10 SharesIssuedForCashShares10	52569	shares
CY2024Q1	RGBP	Shares Issued For Cash10 SharesIssuedForCash10	32362	usd
CY2024Q1	RGBP	Shares Issued For Cash Shares11 SharesIssuedForCashShares11	44503	shares
CY2024Q1	RGBP	Shares Issued For Cash11 SharesIssuedForCash11	25282	usd
CY2024Q1	RGBP	Shares Issued For Cash Shares12 SharesIssuedForCashShares12	49230	shares
CY2024Q1	RGBP	Shares Issued For Cash12 SharesIssuedForCash12	26781	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	10050	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-54978	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-4929755	usd
	us-gaap	Net Income Loss NetIncomeLoss	-472233	usd
	us-gaap	Net Income Loss NetIncomeLoss	1580752	usd
	RGBP	Preferred Stock Issued As Compensation PreferredStockIssuedAsCompensation	-348372	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	8706	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	124	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5248	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	39723	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-175150	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-171	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	29444	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-5200	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-13714	usd
	RGBP	Increase Decrease In Contributed Capital IncreaseDecreaseInContributedCapital	0	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-2151755	usd
	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	-78407	usd
	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	-63280	usd
	RGBP	Gain Loss On Forgiveness Of Debt GainLossOnForgivenessOfDebt	-0	usd
	RGBP	Gain Loss On Forgiveness Of Debt GainLossOnForgivenessOfDebt	1150	usd
	RGBP	Unrealized Lossgain On Investment Securities UnrealizedLossgainOnInvestmentSecurities	-204847	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-371657	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-63504	usd
	RGBP	Increase Decrease In Convertible Notes Payable IncreaseDecreaseInConvertibleNotesPayable	-10000	usd
	us-gaap	Increase Decrease In Notes Payable Current IncreaseDecreaseInNotesPayableCurrent	-61500	usd
	us-gaap	Increase Decrease In Notes Payable Current IncreaseDecreaseInNotesPayableCurrent	100000	usd
	RGBP	Increase Decrease In Common Stock Issued For Cash IncreaseDecreaseInCommonStockIssuedForCash	400234	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	328734	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	100000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-42923	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	36949	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	121037	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51204	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78114	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	87700	usd
	RGBP	Preferred Share Issued For Debt PreferredShareIssuedForDebt	761500	usd
	RGBP	Common Shares Issued For Interests CommonSharesIssuedForInterests	25369	usd
	RGBP	Preferred Shares Issued For Interests PreferredSharesIssuedForInterests	380262	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0539	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	9.3298	pure
	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	1	pure
	us-gaap	Advertising Expense AdvertisingExpense	0	usd
	RGBP	Net Income Loss Since Inception NetIncomeLossSinceInception	20221096	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5800000000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4114622	shares
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	800000000	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	39638	usd
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	44297	usd
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	19614	usd
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	32362	usd
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	25282	usd
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	26781	usd
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	25326	usd

Files In Submission

Name	View Source	Status
0001607062-24-000131-index-headers.html	Edgar Link	pending
0001607062-24-000131-index.html	Edgar Link	pending
0001607062-24-000131.txt	Edgar Link	pending
0001607062-24-000131-xbrl.zip	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex31_2.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
ex32_2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rgbp-20240331.xsd	Edgar Link	pending
rgbp033124form10q.htm	Edgar Link	pending
Show.js	Edgar Link	pending
rgbp-20240331_def.xml	Edgar Link	unprocessable
rgbp-20240331_lab.xml	Edgar Link	unprocessable
rgbp033124form10q_htm.xml	Edgar Link	completed
rgbp-20240331_cal.xml	Edgar Link	unprocessable
rgbp-20240331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RGBP
Regen BioPharma Inc Stock $rgbp

2024 Q2 Form 10-Q Financial Statement

#000160706224000131 Filed on April 24, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGBP Regen BioPharma Inc Stock $rgbp

2024 Q2 Form 10-Q Financial Statement

#000160706224000131 Filed on April 24, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGBP
Regen BioPharma Inc Stock $rgbp